Enter Morley Robbins: copper, ceruloplasmin and your genes
This is the third in a four-part series on metals and MND/ALS. Parts 1 and 2 followed the research into the spinal cord: copper displaced rather than simply depleted, zinc accumulating in a reactive form it should not be in, iron driving a form of cell death that researchers only named in 2012. By the end of Part 2, the tissue studies had established something real and replicated: the metal chemistry of a failing motor neurone does not follow any simple pattern of too much or too little. What those studies could not explain was why the same disruption looks different from one person to the next. That is the question this part takes further. Part 4 follows a patient with primary lateral sclerosis (PLS) whose diagnostic journey brings the genetic questions raised here into direct contact with clinical reality.
Some variation in metal disruption will be environmental. Some of it is written into your genes before you are born. This part takes that question somewhere specific: into the biology of a single protein, the genes that shape how your body handles copper, and a health practitioner whose ideas about copper and iron have attracted both a devoted following and serious scientific scrutiny. To make sense of any of it, you need to understand ceruloplasmin.
The protein carrying 95% of your copper has a second job you have never heard of
When copper enters the bloodstream after absorption in the gut, it does not travel free. Around 70 to 95 percent of plasma copper circulates bound to a single protein: ceruloplasmin. (Kunwar et al., 2026) Ceruloplasmin is produced mainly in the liver and, to a lesser extent, in the brain, where specialised support cells called astrocytes make it to help manage metal levels in the surrounding tissue. (Li et al., 2025)
Most people, if they think of ceruloplasmin at all, think of it as a copper carrier. That is accurate but incomplete. Its second job is the one that connects it to the neurodegeneration research in this series. Ceruloplasmin is a ferroxidase: a word that simply means it oxidises iron.
Here is why that matters. When iron leaves cells, it exits in a reduced form called ferrous iron (Fe2+). Left loose in the bloodstream, ferrous iron generates reactive oxygen species (unstable molecules that cause cellular damage) through a chemical reaction it has been running since before multicellular life existed. Ceruloplasmin meets it as it exits, converts it to ferric iron (Fe3+), a stable form, and hands it safely to transferrin, the protein that carries iron in the blood. Without that handover, iron accumulates in tissues where it should not be, and the conditions for oxidative damage and ferroptosis, the iron-driven cell death described in Part 2, are in place. (Tolbatov & Marrone, 2026)
Think of ceruloplasmin as a traffic warden at a busy junction. It does not stop the iron from travelling; it makes sure it travels safely, in the right form, to the right place. Without the warden, iron runs loose.
Here is the critical biological detail: ceruloplasmin can only perform this function when copper is loaded into it at six specific binding sites within the protein. The version of ceruloplasmin that has not yet been loaded with copper is called apoceruloplasmin (the prefix "apo" indicating it is the protein in its empty form). Apoceruloplasmin does not simply sit idle waiting for copper to arrive. It degrades rapidly in the body. So when copper availability falls, or when the machinery that loads copper into ceruloplasmin is faulty, what you lose is not just copper function. You lose ceruloplasmin's ability to manage iron traffic as well (Kunwar et al., 2026).
The loading dock that connects copper to iron: meet ATP7B
Two genes are central to how copper reaches ceruloplasmin. ATP7A governs copper transport in most cells of the body. ATP7B, which is the gene most relevant to the disruption discussed in this series, manages copper specifically in the liver.
ATP7B encodes an enzyme called copper-transporting ATPase 2. Think of this enzyme as the loading dock manager inside liver cells. Copper arrives from the gut, enters liver cells, and is handled by ATP7B in two ways: it is either packaged into bile for excretion, or it is loaded into apoceruloplasmin so that the protein can become active, copper-loaded ceruloplasmin and enter circulation. Without ATP7B doing this job efficiently, the copper that was supposed to activate ceruloplasmin never gets there.
When both copies of ATP7B, one inherited from each parent, carry pathogenic variants, the result is Wilson disease: copper accumulates in the liver and brain while ceruloplasmin levels in the blood fall, because the liver keeps producing apoceruloplasmin but cannot load it with copper. The protein breaks down before it can reach circulation. Both copper overload and copper insufficiency are happening simultaneously in different places. (Gromadzka et al., 2024).
Wilson disease is rare. What makes ATP7B scientifically interesting beyond Wilson disease is the breadth of variation within the gene itself. Over 700 different variants have been identified in ATP7B across populations, making it one of the more genetically variable genes relevant to metal metabolism (Gromadzka et al., 2024). One of the most studied is p.H1069Q, particularly common in people of European descent, which alters how the ATP7B protein folds and functions (Petters et al., 2020). People who carry a single pathogenic ATP7B variant rather than two are typically not clinically unwell, but current research is examining whether copper handling in those individuals differs in ways that do not show up as a diagnosis (Gromadzka et al., 2024).
Alongside ATP7B, the CP gene encodes ceruloplasmin itself. Variants in CP influence the protein's structure, its stability, and how effectively it carries out its ferroxidase function. In the inherited condition aceruloplasminemia, pathogenic CP variants lead to the complete absence of functional ceruloplasmin. The result is progressive iron deposition in the brain, liver, and pancreas, and the eventual neurodegeneration that follows (Kunwar et al., 2026). The absence of ceruloplasmin does not primarily harm the body through copper loss. It harms the body through what happens to iron when there is nothing to make it safe.
Enter Morley Robbins: a framework that takes these questions further than the evidence has gone
Morley Robbins is an American health practitioner and former hospital administrator who came to copper biology through his own health problems. Over more than a decade, he developed what he calls the Root Cause Protocol (RCP): a framework that places copper, ceruloplasmin, and iron at the centre of a wide range of chronic conditions. His book, Cu-RE Your Fatigue, laid out this framework in accessible language and attracted a substantial following in the functional health and chronic illness communities.
His central argument is this: most people in the modern world are not copper toxic. They are copper dysregulated. The problem, in his telling, is not that people have too much copper in their bloodstream, but that the copper they have is not bioavailable, meaning it is not successfully incorporated into functional ceruloplasmin. Ceruloplasmin is present, but underperforming. As a result, iron is not properly trafficked, unbound reactive iron accumulates in tissues, and a cascade of inflammation and oxidative stress follows.
Robbins identifies several factors he believes drive this state: excess supplemental iron, high-dose vitamin D supplements, high-dose vitamin C supplements, and insufficient dietary retinol (the animal-derived form of vitamin A, distinct from the plant-derived beta-carotene). His argument about retinol is specific: he contends that retinol is required for the liver to load copper into ceruloplasmin, so chronic low retinol intake leads to dysfunctional copper metabolism even when a standard blood test shows copper within normal range.
His list of recommended dietary changes, and the things he advises stopping, follows from this framework. The protocol includes removing supplemental iron and recommends dietary beef liver as a source of both copper and retinol. It is an internally consistent framework built on real biochemistry. The question this post is asking is how much of it the peer-reviewed literature actually supports.
The parts of Robbins' framework that are grounded in real science
The foundation is solid. Ceruloplasmin must be loaded with copper to function as a ferroxidase, and apoceruloplasmin without copper breaks down rapidly. This is established biochemistry. (Kunwar et al., 2026) When copper availability is genuinely reduced, ceruloplasmin activity falls, and iron handling is disrupted as a direct result. This connection between copper sufficiency and iron metabolism is not controversial; it is one of the best-supported relationships in trace mineral biochemistry.
The aceruloplasminemia data is striking in this context. People born without functional ceruloplasmin develop progressive iron deposition in the brain, not primarily a copper-related condition, but an iron one, caused by the loss of ceruloplasmin's ferroxidase activity. The copper-iron link Robbins describes has an extreme clinical illustration in this condition (Kunwar et al., 2026).
More directly relevant to this series: the 2024 paper by Hilton and colleagues at the University of Melbourne, which formed part of the foundation of Part 2, found something worth considering alongside Robbins' central premise, though with important caveats about what it does and does not show. In post-mortem spinal cord tissue from people with end-stage sporadic ALS, ceruloplasmin protein abundance was elevated relative to controls. Total copper-dependent ferroxidase activity in that same spinal cord tissue, an activity shared between ceruloplasmin and a related multicopper enzyme called hephaestin, was reduced. (Hilton et al., 2024) The protein was present in greater quantity. The collective function it contributes to was diminished. Two things about this finding need to be held clearly. First, it was a measurement made in post-mortem spinal cord homogenates at end-stage disease. It does not measure circulating ceruloplasmin function or systemic copper status, and the authors state explicitly that the findings cannot be characterised as general nutritional copper insufficiency. Second, this is a cross-sectional tissue study: it cannot establish whether the changes preceded ALS, resulted from it, or both. What it does show is that in ALS-affected spinal tissue, elevated protein abundance and reduced functional activity can coexist, a dissociation that is consistent with the kind of copper dysregulation Robbins proposes as a systemic phenomenon, even though the study itself does not confirm that systemic picture. One further note: Hilton et al. framed their paper as supporting copper-ATSM (a copper delivery compound) as a treatment candidate for sporadic ALS. As of 2026, the International Alliance of ALS/MND Associations moved copper-ATSM to its list of drugs no longer in development, citing no substantiated evidence of clinical benefit in humans. That development does not invalidate the tissue findings Hilton reported; it does affect how the clinical significance of those findings should be read.
The iron trap mechanism that follows from this is described in a 2026 review in the journal Biomolecules: when multicopper ferroxidases including ceruloplasmin are inactive or underperforming, iron becomes trapped in a reactive state, driving exactly the lipid peroxidation and cell death described in ferroptosis (Tolbatov & Marrone, 2026). Robbins arrived at this relationship by reading biochemistry. The biochemistry is real.
There is also limited published evidence that moderately high supplemental vitamin C may reduce ceruloplasmin oxidase activity without necessarily reducing copper absorption or overall copper status. Evidence supporting a clinically important role for retinol in ceruloplasmin loading is limited and appears to be largely preclinical.
Where the research does not follow him
The difficulty begins when Robbins moves from mechanism to prevalence and from mechanism to specific intervention.
His claim that copper dysregulation in the way he describes it is widespread, affecting large numbers of people with varied chronic conditions, is not supported by population-level data. Serum copper and ceruloplasmin levels can be measured in clinical biochemistry when there is a specific reason to look, for example in suspected Wilson disease or copper deficiency following gastric surgery, but they are not routine population screening tests, and widespread functional copper insufficiency is not a recognised finding in populations eating varied diets. True copper deficiency in adults tends to occur in specific, identifiable contexts: prolonged intravenous feeding without copper supplementation, excessive zinc supplementation over extended periods (zinc competes with copper for gut absorption), or after gastric surgery that removes sections of the small intestine where copper is absorbed.
The claim that standard doses of vitamin D or vitamin C, at the levels found in typical over-the-counter supplements, meaningfully impair copper handling and produce the widespread ceruloplasmin dysfunction he describes is not supported by clinical trial evidence. The high-dose ascorbic acid data involves doses well above typical supplemental use, and its clinical relevance to ceruloplasmin function in healthy adults has not been demonstrated.
Perhaps most importantly, the Root Cause Protocol itself has not been tested in clinical trials. The specific sequence of stops and starts Robbins recommends has not been examined in randomised controlled studies for any of the conditions he associates with copper dysregulation, including fatigue, anaemia, or neurological symptoms. His framework is built from biochemistry upward, which means it is a hypothesis, not a proven therapeutic approach.
For someone reading this series because ALS/MND has touched their life, holding this distinction with care is important. The copper and iron disruption documented in the ALS research papers cited here is real, replicated, and published in peer-reviewed journals. The distance from that documented disruption to a specific dietary or supplemental intervention that meaningfully changes the disease course has not been crossed in clinical evidence. Robbins identified a scientifically legitimate question. The research has not yet produced an answer to match the scope of his proposed solution.
What your genes can tell you that a blood test alone cannot
Here is where individual genetics becomes significant, and where the research intersects with what a clinic can actually offer.
Two people with identical serum copper levels may, in principle, handle copper differently at the cellular level depending on the variants they carry in ATP7B (copper-transporting ATPase 2) and CP (the ceruloplasmin gene). The reasoning is biologically plausible: ATP7B variants can influence how efficiently the copper-loading step is performed in the liver, and CP variants can influence the structure and stability of the resulting ceruloplasmin protein. A person with certain ATP7B variants might, in theory, produce ceruloplasmin more slowly or incompletely; a person with certain CP variants might have ceruloplasmin with subtly altered ferroxidase characteristics. It is important to be precise about what is and is not established here. What is firmly established is that pathogenic variants in ATP7B and CP cause rare, clinically serious conditions: Wilson disease and aceruloplasminemia respectively. Whether the common variants assessed in a nutrigenomic panel materially affect copper handling in healthy individuals, or whether they are relevant to amyotrophic lateral sclerosis (ALS) susceptibility or progression, has not been demonstrated in clinical studies. The panel offers exploratory context about individual genetic variation in these pathways: a starting point for a broader clinical conversation, not a standalone measure of copper-handling efficiency.
Hilton et al. found increased abundance of ceruloplasmin and hephaestin alongside reduced total copper-dependent ferroxidase activity in ALS-affected spinal tissue. The study did not determine whether inherited variation in ATP7B, CP or other genes contributed to that finding.
It is also why a blood test measuring total ceruloplasmin tells you something, but not everything. Knowing how much ceruloplasmin is circulating is different from knowing how well it is functioning. And knowing how well it is functioning in the bloodstream is different from knowing whether the genes responsible for loading it with copper, and for producing it in the first place, are working efficiently in a given individual.
What the LifecodeGX metals and minerals panel analyses
Nutrigenomic testing uses genetic analysis to examine how individual genetic variation shapes the way the body handles nutrients and minerals. The LifecodeGX Metals and Minerals panel examines selected variants reported in the research literature across a range of genes involved in metal metabolism and transport.
For copper specifically, the panel analyses ATP7B (the copper-transporting ATPase that loads copper into ceruloplasmin in the liver) and CP (the gene that encodes ceruloplasmin itself). These are the two genes most directly relevant to the copper biology discussed in this series. (LifecodeGx, n.d.)
The panel extends across the metals that interact with copper. Iron handling is covered through HFE and TMPRSS6, two genes relevant to how much iron is absorbed and how iron overload risk is regulated. Zinc transport is assessed through SLC30A8 and SLC39A8. Manganese metabolism includes SOD2, the gene for the mitochondrial superoxide dismutase that uses manganese rather than copper, distinguishing it from the SOD1 enzyme discussed in Part 1. Selenium, which supports antioxidant defence through the glutathione peroxidase family of enzymes, is covered through GPX1, GPX4, and SELENOP. The panel also covers magnesium, calcium, phosphorus, arsenic detoxification, mercury clearance, and sodium-potassium balance. (LifecodeGx, n.d.)
What this offers, in the context of the disruptions described in this series, is a map of individual variation. The ALS research across Parts 1 and 2 describes what tends to happen at a population level in affected spinal cord tissue. Nutrigenomic testing introduces the individual dimension. The panel identifies selected variants in genes involved in metal-related pathways. It has not been shown to quantify an individual's functional capacity to handle copper, iron or zinc, or to predict the course of MND. Two people with the same diagnosis may have very different genetic starting points for managing copper, iron, and zinc. That difference is not destiny, but it provides exploratory context for understanding individual variation in copper and iron handling.
To be clear: this is not a diagnostic test for motor neurone disease, and genetics alone does not cause or predict MND in the way it does for a condition like Wilson disease. What it offers is one part of a more complete picture of individual biochemistry.
Working with someone who can interpret what the genes are saying
Understanding what a nutrigenomic panel means for any individual requires clinical context. A variant in ATP7B does not exist in isolation; it sits alongside a person's full health history, their diet, their other genetic variants, their symptoms, and the results of functional laboratory tests. A genetic report read without that surrounding context risks either over-interpretation, treating a variant as a diagnosis when it is a tendency, or under-interpretation, missing the significance of a finding that only makes sense against a clinical background.
At You Nutrition Clinic, the LifecodeGX Metals and Minerals panel is used as part of a broader consultation approach, where genetic findings are considered alongside clinical history and functional testing rather than in isolation. If you would like to explore whether nutrigenomic testing might be relevant to your situation, or to understand more about what this kind of assessment involves, please get in touch with the clinic.
Where part 4 takes the question
Part 3 has moved the question from the spinal cord to the individual: from what happens in the tissue to why it might happen differently depending on who you are, and from the disruption to the genes that shape the biological response. Robbins drew attention to a legitimate biochemical relationship, even where his answers have travelled further than the current evidence allows. The biology he highlighted, the critical link between copper-loaded ceruloplasmin and safe iron handling, is documented, real, and potentially relevant to abnormalities reported in ALS-affected spinal tissue.
Part 4 leaves the research literature behind entirely. It follows a patient with primary lateral sclerosis whose diagnostic journey raises every question this series has been building: about copper distribution, about genetics, about what it means when the biology stops being theoretical and belongs to someone sitting across from a clinician. It is a clinical narrative, not a proof of mechanism. By that point, the threads this series has laid down pull differently. They are no longer about mechanisms in a laboratory. Each post holds one thread. Together, they pull on something bigger.
🧩 Connect with us
For research updates, practical tips, and ongoing inspiration, follow us on Instagram:
👉 @drkirstielawton
Stay curious. Stay hopeful. Support your brain. 🧠
Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Always consult with a qualified, registered medical doctor (MD) for diagnosis and treatment decisions.
References
Gromadzka, G., Wilkaniec, A., Tarnacka, B., Hadrian, K., Bendykowska, M., Przybylkowski, A., & Litwin, T. (2024). The role of glia in Wilson's disease: Clinical, neuroimaging, neuropathological and molecular perspectives. International Journal of Molecular Sciences, 25(14). https://doi.org/10.3390/ijms25147545
Hilton, J. B. W., Kysenius, K., Liddell, J. R., Mercer, S. W., Paul, B., Beckman, J. S., McLean, C. A., White, A. R., Donnelly, P. S., Bush, A. I., Hare, D. J., Roberts, B. R., & Crouch, P. J. (2024). Evidence for disrupted copper availability in human spinal cord supports Cu(atsm) as a treatment option for sporadic cases of ALS. Scientific Reports, 14(1), 5929. https://doi.org/10.1038/s41598-024-55832-w
International Alliance of ALS/MND Associations. (2026, April). CuATSM. https://www.als-mnd.org/support-for-pals-cals/drugs-no-longer-development/cuatsm/
Kunwar, D., Kumar, J., Ali, S. A., Namdeo, A. G., & Flora, S. J. S. (2026). Ceruloplasmin and neurodegeneration: A link between copper dysregulation, iron imbalance, and neuronal damage. Journal of Trace Elements in Medicine and Biology, 97, 127929. https://doi.org/10.1016/j.jtemb.2026.127929
Li, Z.-D., Kang, S., Li, H., Yu, P., Xie, R., Li, C., Jing, Q., Gong, Z., Li, L., Li, Z., Geng, M., Zhang, Z., Li, Y., & Chang, Y.-Z. (2025). Absence of astrocytic ceruloplasmin reverses the senescence process with aging of learning and memory abilities. Redox Biology, 82, 103611. https://doi.org/10.1016/j.redox.2025.103611
LifecodeGx. (n.d.). Metals and minerals report. https://www.lifecodegx.com/minerals-report
Petters, J., Volkner, C., Krohn, S., Murua Escobar, H., Bullerdiek, J., Reuner, U., Frech, M. J., Hermann, A., & Lukas, J. (2020). Generation of two induced pluripotent stem cell lines from a female adult homozygous for the Wilson disease associated ATP7B variant p.H1069Q. Stem Cell Research, 49, 102079. https://doi.org/10.1016/j.scr.2020.102079
Tolbatov, I., & Marrone, A. (2026). Ferroptosis and cuproptosis in cancer and neurodegeneration: A comprehensive review of modulation by iron and copper chelators and related agents. Biomolecules, 16(3). https://doi.org/10.3390/biom16030348
Comments